Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

Buprenorphine uptake increases as more physicians receive waivers.
FDA approves third migraine prevention medication in the new CGRP class: Lilly's Emgality.
FDA REMS now apply to immediate-release opioid analgesics.
Nearly $200 million in new CDC funds will go to territories, tribes, NGOs, and states to help support opioid awareness and response programs.
SAMHSA releases latest statistics on substance misuse including for prescription opioids, heroin, fentanyl, and more.
Agency is taking steps to advance development of new FDA-approved treatments for opioid dependence.
Stanford scientists discover that ketamine's antidepressive effect is tied to the opioid system in the brain.
As the US Congress prepares to return to session after Labor Day, FDA Commissioner Scott Gottlieb, MD, has taken the opportunity to outline his agency’s work on the opioid crisis over the past 8 months.
FDA tackles opioid epidemic by focusing on rational prescribing practices for the treatment of acute pain.
Pennsylvania-based biotech company Braeburn has a PDUFA target date of December 26, 2018 for its buprenorphine injectable aimed at treating opioid use disorder (OUD) in adults.
A new survey shows that migraine sufferers are largely unaware of the new preventive CGRP medication class.
Numerous studies have shown the powerful impact that lifestyle medicine can have on patients as part of an integrative approach.
A new pain assessment tool may be coming soon to clinical trials for better, individualized treatment approaches.
Agency is encouraging developers to innovate against opioid misuse.